MELANOTAN I RESEARCH UPDATES
Melanotan 1 Research Updates: Current Status
An approved rare-disease product; watch for new indications
Melanotan 1 research updates concern its approved pharmaceutical form, afamelanotide (SCENESSE), and any exploration of additional light-related conditions.
Where Things Stand
SCENESSE has been approved since 2019 for increasing pain-free light exposure in adults with EPP. Research into other light-sensitivity conditions has been explored, but that does not change the current approved use.
Source: FDA prescribing information for SCENESSE.
What to Watch
- Any new approved indications for afamelanotide (none broadly added as of this review).
- The continued distinction between the approved implant and research-labeled "MT-1".
Frequently Asked Questions
Has SCENESSE gained new uses?
Not broadly as of this review; it remains approved for EPP.
The Bottom Line
Melanotan 1 research updates track the approved afamelanotide product and any new indications.
This article is for general educational purposes only. It is not medical advice and should not be used to diagnose, treat, or make decisions about any health condition or medication.
Primary Sources
- FDA prescribing information for SCENESSE (afamelanotide)
Wellness should feel clear, personal, and supported.
Start with education, ask the right questions, and take the next step with confidence.
Get in touch →